Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma

Hematological Oncology

Volumn 32, Issue 4, 2014, Pages 221-224

  Lee, Seung Eun ^a   Kang, So Young ^a   Takeuchi, Kengo ^b   Ko, Young Hyeh ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COMPLEMENTARY DNA; RNA; CHAPERONE; NUCLEOPORIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAN-BINDING PROTEIN 2;

ALK GENE; CANCER TISSUE; DIFFUSE LARGE B CELL LYMPHOMA; DNA SEQUENCE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUSION; HUMAN; LETTER; RANBP2 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; CELL NUCLEUS; CYTOPLASM; GENE TRANSLOCATION; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

CELL NUCLEUS; CYTOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR CHAPERONES; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84914095965     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2125     Document Type: Letter

References (13)

1. Delasol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In Who classification of tumours of haematopoietic and lymphoid tissues. Swerdlow S, Campo E, Harris N, et al. (eds). WHO press: Geneva, 2008; 254-255.
2. Adam P, Katzenberger T, Seeberger H, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am. J. Surg. Pathol. 2003; 27: 1473-1476.
3. Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003; 102: 2642-2644.
4. Lee HW, Kim K, Kim W, Ko YH. ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol. Oncol. 2008; 26: 108-113.
5. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003; 37: 98-105.
6. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483-1490.
7. Bedwell C, Rowe D, Moulton D, Jones G, Bown N, Bacon CM. Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Haematologica 2011; 96: 343-346.
8. d'Amore ES, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am. J. Surg. Pathol. 2013; 37: 780-786.
9. Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011; 96: 464-467.
10. Van Roosbroeck K, Cools J, Dierickx D, et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010; 95: 509-513.
11. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 2005; 11: 623-629.
12. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047.
13. Momose S, Tamaru J, Kishi H, et al. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum. Pathol. 2009; 40: 75-82.